Physician
Pathology
Dr. Constance T. Albarracin, MD
|
|
Give Review
Dr. Constance T. Albarracin works in the field of Pathology. Constance Albarracin has written publications. He has 59 publications published with PubMed. The lastest paper is: 'High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors.' He is registered with Medicare.
Publications
- High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors.
- The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemo-resistance in esophageal cancer.
- Molecular cytogenetic characterization of mammary neuroendocrine carcinoma.
- Predictors that Influence Contralateral Prophylactic Mastectomy Election Among Women with Ductal Carcinoma In Situ Who Were Evaluated for BRCA Genetic Testing.
- Multi-institutional comparison of whole slide digital imaging and optical microscopy for interpretation of hematoxylin-eosin-stained breast tissue sections.
- The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer.
- Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.
- Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast.
- Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
- Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass.
- Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis.
- Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
- Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience.
- Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.
- Distinct function of androgen receptor coactivator ARA70α and ARA70β in mammary gland development, and in breast cancer.
- Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in...
- Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges.
- Management of radial sclerosing lesions of the breast diagnosed using percutaneous vacuum-assisted core needle biopsy: recommendations for excision based on seven year...
- The stimulation of HSD17B7 expression by estradiol provides a powerful feed-forward mechanism for estradiol biosynthesis in breast cancer cells.
- Atypical ductal hyperplasia in directional vacuum-assisted biopsy of breast microcalcifications: considerations for surgical excision.
- Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation.
- Triple-negative breast cancer: what the radiologist needs to know.
- Identifying patients with atypical ductal hyperplasia diagnosed at core-needle biopsy who are at low risk of malignancy.
- Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.
- Clinical and radiologic data and core needle biopsy findings should dictate management of cellular fibroepithelial tumors of the breast.
- Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution re...
- Is it too soon to start reporting HER2 genetic heterogeneity?
- Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.
- MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.
- Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma.
- Survival among women with triple receptor-negative breast cancer and brain metastases.
- High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.
- Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.
- Ductal carcinoma in situ: state of the science and roadmap to advance the field.
- Loss of annexin A1 expression in breast cancer progression.
- MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers.
- Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
- Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
- Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
- Pseudoangiomatous stromal hyperplasia tumor: a clinical, radiologic and pathologic study of 26 cases.
- Development of new cancers in patients with DCIS: the M.D. Anderson experience.
- Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma.
- Giant cell tumor of soft tissue arising in breast.
- Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
- Profile of Ets gene expression in human breast carcinoma.
- Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biops...
- Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
- A large, fungating breast mass. Secretory carcinoma with apocrine differentiation.
- Collagenous spherulosis of breast: morphologic study of 59 cases and review of the literature.
- Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis.
- A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding.
- The role of hMSH3 and hMSH6 in ovarian endometrioid carcinoma and relationship with microsatellite instability phenotype.
- Expression of sigma 1 receptor in human breast cancer.
- Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma.
- Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer.
- Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma.
- Suppression of Akt-mTOR Pathway-A Novel Component of Oncogene Induced DNA Damage Response Barrier in Breast Tumorigenesis.
- Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database.
Doctors Specialties
- Pathology
Accepted Insurances
- American Republic
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- GEHA
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
University of Chicago -
University of Santo Tomas
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1255424073 |
| Last Name Of The Provider | ALBARRACIN |
| First Name Of The Provider | CONSTANCE |
| View All |
Similar Doctors
|
|
Dr. Rose C. Anton, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley R. Hamilton, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Rhonda P. Ghorbani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shylashree C. Chikkamuniyappa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nina Tatevian, MD
This Doctor is OpenDoctor Recommended.
|